David Mott, non-executive director of biopharmaceutical giant Shire has topped up his stake in the company through a purchase of American Depositary Receipts (ADRs).
Pharmaceuticals veteran Mott took his holding in Shire up to 25,000 ADRs through the purchase of 5,000 ADRs at a price of $38.6737 each.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Mott joined the board of Shire as a non-executive direction in November 2007.
He was formerly Chief Executive Officer and President of US drugs company MedImmune, and banked $286.7m when the company was acquired by AstraZeneca in June 2007.
Mott also served as an executive vice president of AstraZeneca before stepping down at the end of July 2008.
Prior to joining MedImmune Mott was vice president in the Health Care Investment Banking Group at stockbrokers Smith Barney.
His latest purchase of Shire shares follows a poor reaction to the company's full year results last week.
Fourth quarter sales rose by 6% to $770m, while net income for the quarter rose to $185m from $177m.
Analysts suggested that sales of Liadi, for ulcerative colitis, and Elaprase, for Hunter's syndrome, were a bit below expectations.
Top Director Buys
Value: £133,960
Value: £94,570
Value: £91,918
Value: £87,806
Value: £87,452
Value: £91,450
Value: £55,104
Value: £50,000
Value: £45,567
Value: £29,861
Top Director Sells
None
-
1.9 million owed £240 million in unclaimed energy credit – are you due a payout?Energy regulator Ofgem is urging home movers to check if they’ve got credit stuck in old accounts
-
More pensioners dragged into 60% tax trap – could you be caught?Frozen thresholds are pushing more older workers into paying income tax at levels much higher than the headline rate, new figures show. We look at why and how you can avoid being caught in the 60% tax trap.
